B. Metzler seel. Sohn & Co. AG boosted its holdings in DocuSign, Inc. (NASDAQ:DOCU - Free Report) by 72.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,677 shares of the company's stock after buying an additional 3,652 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in DocuSign were worth $780,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of DOCU. Kestra Investment Management LLC purchased a new position in shares of DocuSign during the fourth quarter valued at approximately $30,000. First Horizon Advisors Inc. raised its stake in DocuSign by 102.6% during the 4th quarter. First Horizon Advisors Inc. now owns 397 shares of the company's stock valued at $36,000 after buying an additional 201 shares during the last quarter. Modus Advisors LLC purchased a new stake in DocuSign during the 4th quarter valued at $36,000. Avion Wealth lifted its holdings in shares of DocuSign by 309.2% during the 4th quarter. Avion Wealth now owns 487 shares of the company's stock valued at $43,000 after buying an additional 368 shares during the period. Finally, Avior Wealth Management LLC boosted its stake in shares of DocuSign by 36.5% in the 4th quarter. Avior Wealth Management LLC now owns 542 shares of the company's stock worth $49,000 after buying an additional 145 shares during the last quarter. Institutional investors own 77.64% of the company's stock.
Insider Buying and Selling
In related news, Director Teresa Briggs sold 534 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $87.41, for a total value of $46,676.94. Following the completion of the sale, the director now directly owns 8,270 shares in the company, valued at $722,880.70. This trade represents a 6.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Blake Jeffrey Grayson sold 8,000 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $86.90, for a total transaction of $695,200.00. Following the transaction, the chief financial officer now owns 77,851 shares in the company, valued at $6,765,251.90. This trade represents a 9.32 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 57,851 shares of company stock worth $4,911,319. Insiders own 1.66% of the company's stock.
DocuSign Stock Down 6.7 %
DOCU stock traded down $5.16 during midday trading on Friday, hitting $72.21. The company's stock had a trading volume of 2,881,620 shares, compared to its average volume of 2,700,521. DocuSign, Inc. has a 12 month low of $48.70 and a 12 month high of $107.86. The company has a 50 day moving average of $86.02 and a two-hundred day moving average of $81.98. The firm has a market capitalization of $14.62 billion, a price-to-earnings ratio of 14.89, a price-to-earnings-growth ratio of 6.94 and a beta of 1.20.
DocuSign (NASDAQ:DOCU - Get Free Report) last issued its earnings results on Thursday, March 13th. The company reported $0.86 earnings per share for the quarter, topping analysts' consensus estimates of $0.84 by $0.02. The firm had revenue of $776.25 million during the quarter, compared to analyst estimates of $760.94 million. DocuSign had a net margin of 34.73% and a return on equity of 14.90%. DocuSign's revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.76 earnings per share. On average, analysts anticipate that DocuSign, Inc. will post 1.17 earnings per share for the current fiscal year.
Analysts Set New Price Targets
DOCU has been the topic of a number of recent research reports. UBS Group lowered their target price on DocuSign from $100.00 to $90.00 and set a "neutral" rating on the stock in a report on Friday, March 14th. Wells Fargo & Company increased their price objective on shares of DocuSign from $70.00 to $73.00 and gave the stock an "underweight" rating in a research note on Friday, March 14th. HSBC restated a "reduce" rating on shares of DocuSign in a research report on Friday, December 6th. Needham & Company LLC reissued a "hold" rating on shares of DocuSign in a research report on Friday, March 14th. Finally, William Blair raised DocuSign from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, DocuSign currently has an average rating of "Hold" and an average price target of $95.83.
Get Our Latest Research Report on DocuSign
About DocuSign
(
Free Report)
DocuSign, Inc provides electronic signature solution in the United States and internationally. The company provides e-signature solution that enables sending and signing of agreements on various devices; Contract Lifecycle Management (CLM), which automates workflows across the entire agreement process; Document Generation streamlines the process of generating new, custom agreements; and Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce.
Featured Articles

Before you consider DocuSign, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DocuSign wasn't on the list.
While DocuSign currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.